Page 13 of 282: studies 121 to 130 of 2,815, newest first. Back to the LSD overview
Drogues santé et société 2025 Frédéric Robert
Les années soixante aux États-Unis ont été une décennie turbulente. L’un des principaux éléments de cette transformation sociale, sociétale et culturelle est sans nul doute la « révolution psychédélique » qui a profondément secoué la Californie en général et le quartier de Haight-Ashbury à San Francisco en particulier. La déferlante psychédélique a radicalement transformé la Californie. Le...
Biologie aujourd'hui 2025 Amel Bouloufa, Sarah Delcourte, Nasser Haddjeri
Major depressive disorder (MDD) is a prevalent and disabling condition affecting over 350 million individuals worldwide. Although conventional antidepressants targeting serotonin, dopamine, and noradrenaline pathways provide benefit for many, a substantial proportion of patients experience inadequate response. Treatment-resistant depression (TRD), defined by failure to respond to at least two...
Drug Testing and Analysis 2025 Pierce V. Kavanagh, Folker Westphal, Benedikt Pulver et al. 8 citations
1-Acetyl-N,N-diethyllysergamide (1A-LSD, ALD-52) was first synthesized in the 1950s and found to produce psychedelic effects similar to those of LSD. Evidence suggests that ALD-52 serves as a prodrug in vivo and hydrolysis to LSD is likely responsible for its activity. Extension of the N1-alkylcarbonyl chain gives rise to novel lysergamides, which spurred further investigations into their...
The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association 2025 Melissa Bradley, Daniel H. Grossman, Otto Simonsson et al. 1 citation
Recent legislative initiatives in the United States have focused on the medical and legal status of psychedelics, prompting interest in understanding public perceptions of their risks. This study investigates rural-urban differences in the perception of LSD and cannabis risks using national survey data. Data from the National Survey of Drug Use and Health (NSDUH) between 2015 and 2021 were...
bioRxiv Preprint Server December 12, 2024 Lauri Elsilä, Elina Nagaeva, Jari-Pekka Luukkonen et al. 1 citation preprint
The current research on psychedelic compounds such as lysergic amide diethylamide (LSD) is leaning heavily on the notion that psychedelics are not addictive. While much of the literature supports this argument, some of the common use patterns and the descriptions of the subjective effects of these compounds in humans, together with rather lacking and mixed data from non-human animal studies...
Revista Ibero-Americana de Humanidades, Ciências e Educação December 4, 2024 Tamyres Cordeiro Leoncio, Danilo Cândido de Araújo Batista
O LSD (dietilamida do ácido lisérgico), tradicionalmente conhecido por seus efeitos psicodélicos, tem atraído crescente interesse na pesquisa científica devido ao seu potencial terapêutico em uma série de distúrbios neurológicos e psiquiátricos. Este artigo revisa as evidências recentes sobre os efeitos do LSD, destacando sua capacidade de promover a neuroplasticidade, modular o sistema...
Drug Testing and Analysis December 3, 2024 Simon D. Brandt, Pierce V. Kavanagh, Sarah Gare et al. 5 citations
The classical psychedelic drug (+)-lysergic acid diethylamide (LSD) continues to attract considerable multidisciplinary interest, and over the last eight decades, many derivatives and analogs of LSD have been synthesized. One site on the ergoline scaffold of LSD that has been frequently modified is the N1-position, with the N1-acylated LSD derivative 1-acetyl-LSD (1A-LSD, ALD-52) being one of...
Veterinary research communications December 1, 2024 Luis Alberto Henríquez-Hernández, Ignacio García-Serrano, Domingo J Quintana-Hernández et al. 4 citations
Anxiety affects 14-20% of dogs. Pharmacological treatments often fail. Psychedelics have shown to be useful for anxiety and depression in humans, but their veterinary use remains unexplored. We aimed to determine the effects of low-dose 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) administered in a single dose to a dog, to observe the effect and establish the safety of the substance....
Psychedelic Medicine December 1, 2024 Connor J Haggarty, Hanna Molla, James Glazer et al. 2 citations
Despite widespread popular interest in the use of low doses of Lysergic acid diethylamide (LSD) to improve mood, little is known about how these doses affect emotional processing in the brain. In this study, we tested the effect of a single low dose of LSD (26 µg) compared with placebo on electroencephalogram (EEG) event-related potentials (ERP: N170, P300 and Mismatch Negativity) in healthy...
Revista Eletrônica Acervo Saúde October 18, 2024 Lucas Siqueira Dos Santos, João Marcos Santos Oliveira, Layane Estefany Siqueira Dos Santos
Objetivo: Analisar as consequências para a saúde mental provocadas pelo consumo do Dietilamida do Ácido Lisérgico (LSD) e metilenodioximetanfetamina (MDMA) por jovens e adolescentes. Revisão bibliográfica: Este artigo promove uma discussão e análise acerca do consumo desenfreado de LSD e MDMA por jovens e adolescentes. O crescimento exponencial do mercado ilegal do tráfico de drogas e a criação...